echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The clinical study of the new coronavirus inactivated vaccine I/II in Coxing Zhongwei was blinded

    The clinical study of the new coronavirus inactivated vaccine I/II in Coxing Zhongwei was blinded

    • Last Update: 2020-06-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Guide: Preliminary results show that the vaccine has good safety and immunogenicityyesterday, Kexing issued a news report that: Recently, Kexing Holdings Biotechnology Co., Ltdof Beijing Kexing Zhongwei Biotechnology Co., Ltddeveloped a new coronavirus inactivated vaccine Keraif ("New Crown Vaccine") I/II clinical research (0,14 procedures) blind audit and unveiling will be held in BeijingPreliminary results show that the vaccine has good safety and immunogenicitythis randomized, double-blind, placebo-controlled Phase I/II clinical study was conducted by the Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Institute of Public Health), and the purpose of the study was to evaluate the safety, tolerance and immunogenty of the vaccine in accordance with the safety, tolerance and immunogenicity of healthy subjects in different doses of the new coronavirus inactivated vaccine in accordance with the 0, 14 procedure or 0,28 proceduresTo date, a total of 743 participants in phase I/II clinical studies have completed their vaccinationsthe blinding 0,14 procedure I/II safety data show that the adverse reactions of the vaccine to 1 level mainly, mainly reflected in the vaccination site of mild pain, fatigue and low fever of individual subjects, no serious adverse reactions reportedPhase II clinical studies 0, 14-day program immunogenicity results showed that the total immunity after 14 days of neutralizing antibody impotence rate of more than 90%, indicating that the vaccine has good immunogenicityThe results of the study will be shared with the world as soon as possible in the form of academic papersthe above results support the development of Phase III clinical studies of the new crown vaccine in Kosing ZhongweiThe Company plans to submit to the State Drug Administration a Phase II Clinical Research Report and A-Phase III Clinical Research Program in advance, with a view to initiating Phase III clinical research and vaccine applications as soon as possible
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.